The conditions
that matter most.
Where the platform is pointed.
Oncology
Cancers where current standards of care leave the greatest unmet need: a priority field for platform-derived therapeutic approaches.
Cardiometabolic
Chronic cardiovascular and metabolic disease, where scale of population burden and durability of treatment effect both matter.
Neurology
Neurological conditions with limited disease-modifying options, where delivery and engineering are as decisive as the target.
Rare Disease
Rare and orphan conditions where a focused platform can move with speed and where patient communities are too often overlooked.
A note.
Alifarc is a pre-operational company. The areas above describe where the platform is being directed, not approved products or active clinical programmes. No statement on this page should be read as a claim of safety, efficacy, or availability of any therapy.
Request the data room